Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, China.
Scand J Rheumatol. 2010 Mar;39(2):148-54. doi: 10.3109/03009740903292304.
To perform a meta-analysis to assess the risk of the Fc-gamma receptor type IIIA (FcgammaRIIIA)-V/F158 polymorphism for lupus nephritis and systemic lupus erythematosus (SLE).
We surveyed studies on V/F158 and SLE and/or lupus nephritis using Medline, Blackwell, and EMBASE databases up to January 2009. Sufficient original data were available to calculate odds ratios (ORs) for SLE and/or lupus nephritis based on the American College of Rheumatology (ACR) criteria. Two investigators independently assessed the data quality and extracted the data.
The F158 allele presented overall consistent association evidence for SLE, SLE without nephritis, and lupus nephritis [OR 1.27, 95% confidence interval (CI) 1.13-1.43; OR 1.20, 95% CI 1.05-1.37; OR 1.15, 95% CI 1.04-1.28, respectively]. FF homozygosity had a dose-response relationship for SLE with maximal OR 1.68 (95% CI 1.26-2.23). It also strongly influenced the risk of lupus nephritis and of SLE without nephritis, with maximal OR 1.30 (95% CI 1.04-1.64) and 1.43 (95% CI 1.07-1.92), respectively. Ethnic subgroup analyses revealed that the F158 allele was significantly higher in SLE patients of European and Asian descent [OR 1.30 (95% CI 1.07-1.58) and OR 1.24 (95% CI 1.04-1.48), respectively] but not in SLE patients of African descent and was only highly associated with lupus nephritis in those of Asian descent [OR 1.26 (95% CI 1.06-1.50)]. The FF genotype was significantly associated with SLE in those of European and Asian descent, with maximal OR 1.61 (95% CI 1.03-2.53) and 1.70 (95% CI 1.12-2.58), respectively, but not for lupus nephritis and SLE without nephritis of any subgroup.
The FcgammaRIIIA-V/F158 polymorphism might be a common susceptibility factor for SLE and lupus nephritis and play an important role in the overall development of SLE, showing different risks within ethnic populations, which should provide novel insights into the pathogenesis of the disease.
进行荟萃分析以评估 Fcγ 受体 IIIA 型（FcγRIIIA）-V/F158 多态性与狼疮肾炎和系统性红斑狼疮（SLE）的风险。
我们使用 Medline、Blackwell 和 EMBASE 数据库检索了截至 2009 年 1 月有关 V/F158 和 SLE 及/或狼疮肾炎的研究。根据美国风湿病学会（ACR）标准，有足够的原始数据可用于计算 SLE 和/或狼疮肾炎的优势比（OR）。两位研究人员独立评估数据质量并提取数据。
F158 等位基因与 SLE、无肾炎的 SLE 和狼疮肾炎总体呈一致的关联证据[OR 1.27，95%置信区间（CI）1.13-1.43；OR 1.20，95%CI 1.05-1.37；OR 1.15，95%CI 1.04-1.28]。FF 纯合子与 SLE 的剂量反应关系最大，OR 为 1.68（95%CI 1.26-2.23）。它还强烈影响狼疮肾炎和无肾炎的风险，最大 OR 分别为 1.30（95%CI 1.04-1.64）和 1.43（95%CI 1.07-1.92）。亚组分析表明，欧洲和亚洲血统的 SLE 患者中 F158 等位基因明显较高[OR 1.30（95%CI 1.07-1.58）和 OR 1.24（95%CI 1.04-1.48）]，而非洲血统的 SLE 患者则没有，并且仅与亚洲血统的狼疮肾炎高度相关[OR 1.26（95%CI 1.06-1.50）]。FF 基因型与欧洲和亚洲血统的 SLE 显著相关，最大 OR 分别为 1.61（95%CI 1.03-2.53）和 1.70（95%CI 1.12-2.58），但与任何亚组的狼疮肾炎和无肾炎无关。
FcγRIIIA-V/F158 多态性可能是 SLE 和狼疮肾炎的常见易感因素，并在 SLE 的总体发展中发挥重要作用，在不同种族人群中具有不同的风险，这应该为疾病的发病机制提供新的见解。
